Vor Biopharma clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   Telitacicept · Generalized Myasthenia Gravis (UPSTREAM MG)

   Enrollment closed, study ongoing

   Also in this update: Trial sites expanded: 111 → 120 locations; Primary completion moved earlier from May 2027 to Mar 2027

   Vor Biopharma·Phase 3· NCT06456580· Registry history of NCT06456580 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Minor

   UPSTREAM SjD · Telitacicept in Active Primary Sjögren's Disease

   Trial sites expanded: 43 → 49 locations

   Vor Biopharma·Phase 3· NCT07404865· Registry history of NCT07404865 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.